抗乙型肝炎病毒核苷（酸）类似物不良反应管理专家共识

摘要

Nucleos(t)ide analogues (NAs) are the main agents in anti-HBV therapy. NAs are potent in inhibiting HBV replication and have good safety proifles. With more and more patients are taking NAs, case reports about the side effects on kidney, bone, muscle and neurological are also increasing. The incidences of these side effects are very low, but they may cause severe consequences. To optimize the management of NAs related side effects, we drafted the experts’ consensus on management of side effects of nucleos(t)ide analogues for hepatitis B virus.%核苷（酸）类似物（NAs）是当前慢性乙型肝炎抗病毒治疗的主要药物，NAs具有迅速抑制HBV复制和安全性良好的特点，但随着NAs的应用推广，NAs相关的肾脏、骨骼、肌肉及神经系统等不良反应的报道逐渐增加，这些不良反应的总体发生率并不高，但如不及时发现与处理有可能引起较为严重的临床后果。为优化NAs相关不良反应的临床管理，抗乙型肝炎病毒核苷（酸）类似物不良反应管理专家委员会结合最新的循证医学证据形成本共识。